ANDA 40674, held by Hikma. Codeine Phosphate; Phenylephrine Hydrochloride; Promethazine Hydrochloride.
As of Nov 16, 2026, ANDA 40674 (Promethazine Hydrochloride, Phenylephrine Hydrochloride W/Codeine Phosphate), held by Hikma, was first approved by FDA on Dec 23, 2014, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 23, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Promethazine Hydrochloride, Phenylephrine Hydrochloride W/Codeine Phosphate10MG/5ML;5MG/5ML;6.25MG/5ML · syrup;oral | Codeine Phosphate; Phenylephrine Hydrochloride; Promethazine Hydrochloride | Discontinued |
| Dec 22, 2025 | Supplement 14Labeling · Standard review | Approved | None posted |
| Dec 15, 2023 | Supplement 12Labeling · Standard review | Approved | None posted |
| Jun 28, 2018 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jun 22, 2018 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 29, 2017 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 29, 2017 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jan 13, 2017 | Supplement 2Labeling · Standard review | Approved | None posted |
| Dec 23, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters